Send to

Choose Destination
Gynecol Endocrinol. 2017 Aug;33(8):638-643. doi: 10.1080/09513590.2017.1306735. Epub 2017 May 1.

New AMH assay allows rapid point of care measurements of ovarian reserve.

Author information

a INVICTA Fertility and Reproductive Center , Gdansk , Poland.
b Department of Obstetrics and Gynecological Nursing , Faculty of Health Sciences, Medical University of Gdansk , Gdansk , Poland , and.
c Department of Gynecological Endocrinology , Medical University of Warsaw , Warsaw , Poland.


In this study, we compare two commercial automated immunoassays used to evaluate serum anti-Müllerian hormone (AMH) levels as a prognostic value for ovarian response and pregnancy outcome in assisted reproductive technology cycles. Serum AMH was measured for 193 women. We performed a simultaneous measurement in serum AMH with the two alternative kits VIDAS® and Elecsys® AMH assay. For all women undergoing in vitro fertilization cycle, we collected data on their antral follicle count (AFC) and numbers of retrieved cumulus oocyte complexes (OC) and metaphase II oocytes and pregnancy outcome. The AMH values provided by VIDAS® were correlated with the values obtained with Elecsys® (0.977 for fresh and 0.971 for the frozen samples). For both assays AMH exhibited a moderate positive correlation with AFC, OC and MII oocytes (0.612, 0.674, 0.605 for VIDAS® and 0.570, 0.617, 0.530 for Elecsys®, respectively). AMH prediction of biochemical and clinical pregnancy was similar. The present results suggest that the VIDAS® AMH assay is broadly comparable to the Elecsys-AMH assay in terms of technical performance for clinical or epidemiological use. Both automated assays performed in a similar way and the choice of assay can be made depending on the technical configuration of each laboratory.


Anti-Müllerian hormone; Elecsys AMH assay; VIDAS AMH assay; clinical outcome; comparison of method

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center